DUX4 and facioscapulohumeral muscular dystrophy: Indeed, the treatment of FSHD myotubes with 2′-O-methyl bases on a phosphorothioate backbone, targeting splice sites of exons 2 and 3, reduced endogenous DUX4 by up to 50% and reduced FSHD marker expression [41,45].